Category: Zacks Small Cap Research

123416720 / 1663 POSTS
By Lisa Thompson NASDAQ:IDBA READ THE FULL IDBA RESEARCH REPORT Q1 showed more product launches and design wins albeit at a slower pace than expected due to the worldwide chip shortage. While IDEX (NASDAQ:IDBA) was able to deliver its part, shortages ...
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced the departure of its CEO—Geoff Green—who is leaving “to pursue new opportunities,” effective June 1, 2022. Chief Medical Officer K. Chris Min will ...
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released 2021 operational and financial results in a press release on May 12, 2022, subsequently filing its 10-Q with the SEC and hosting ...
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter 2022 results in a press release and held a conference call after market close on May 12, 2022. The company concu ...
By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT On May 12, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its first quarter 2022 operational and financial results and filed its Form 10-Q for the three month period ending Mar ...
By Lisa Thompson NASDAQ:BRAG READ THE FULL BRAG RESEARCH REPORT Bragg (NASDAQ:BRAG) reported that its Q1 revenue and EBITDA were above expectations. This was primarily due to its exceptional performance in the Dutch market. By geography, that country ...
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT On May 11, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 1Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K. A conference call and w ...
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Cocrystal Pharma (NASDAQ:COCP) reported 2022 1st quarter results on May 11, 2022. For the quarter, the company reported no revenues compared to our expectations that it was possible t ...
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update On May 10, 2022, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) provided additional details from the positive pharmacodynamic (PD) study of OPNT003, for which the company ...
By Lisa Thompson OTC:PKKFF READ THE FULL PKKFF RESEARCH REPORT Revenues in 2021 grew an amazing 143% to CN$104 million despite lockdowns, supply chain issues and delays. The company expanded into new verticals, added an insurance product and importan ...
123416720 / 1663 POSTS